Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
05/2012
05/10/2012US20120114657 Human Monoclonal Antibody Specific for Lipopolysaccharides (LPS) of Serotype IATS 01 of Pseudomonas Aeruginosa
05/10/2012US20120114656 Human Monoclonal Antibodies Protective Against Bubonic Plague
05/10/2012US20120114655 Xylan utilization regulon for efficient bioprocessing of hemicellulose and uses thereof
05/10/2012US20120114654 Human antibodies to human tnf-like ligand 1a (tl1a)
05/10/2012US20120114653 Antibody therapy for treatment of diseases associated with gluten intolerance
05/10/2012US20120114652 Anti-pai-1 antibodies and methods of use thereof
05/10/2012US20120114651 Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue
05/10/2012US20120114650 Single chain antibodies against beta-amyloid peptide
05/10/2012US20120114649 Compositions of pd-1 antagonists and methods of use
05/10/2012US20120114648 Compositions of pd-1 antagonists and methods of use
05/10/2012US20120114647 anti-serum album single variable domains
05/10/2012US20120114646 Lyophilized formulations for small modular immunopharmaceuticals
05/10/2012US20120114645 Use of il-1 antagonists to treat pseudogout
05/10/2012US20120114644 Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
05/10/2012US20120114643 4-pyridinone compounds and their use for cancer
05/10/2012US20120114642 Targeting vegf-b regulation of fatty acid transporters to modulate human diseases
05/10/2012US20120114641 Therapeutic combination comprising a plk1 inhibitor and an antineoplastic agent
05/10/2012US20120114640 MODULATION OF THE TGF- ß AND PI3K/AKT PATHWAYS IN THE DIAGNOSIS AND TREATMENT OF SQUAMOUS CELL CARCINOMA
05/10/2012US20120114639 Compositions and methods for inhibiting viral and/or bacterial infections
05/10/2012US20120114638 Combination therapy
05/10/2012US20120114637 Mtor pathway inhibitors for treating ocular disorders
05/10/2012US20120114636 Low molecular weight cyclin e (lmw-e) as a biomarker for personalization of cancer therapies
05/10/2012US20120114635 Antibodies to cross-linked amyloid beta oligomers
05/10/2012US20120114634 Methods for inducing a sustained immune response against a b-cell idiotype using autologous anti-idiotypic vaccines
05/10/2012US20120114633 Inhibitors Of Bacterial Type III Secretion System
05/10/2012US20120114603 Ifn-alpha/beta-independent mechanism of antiviral protection through a novel ligand-receptor pair: ifn- ligands engage a novel receptor ifn-rn (crf2-12) and il-10r2 (crf2-4) for signaling andinduction of biological activities
05/10/2012US20120114599 Opioid and opioid-like compounds and uses thereof
05/10/2012US20120114597 Cd4+cd25- t cells and tr1-like regulatory t cells
05/10/2012US20120114596 Tslp promotes immune evasion and persistence of viruses
05/10/2012US20120114593 Method and composition for altering a b cell mediated pathology
05/10/2012US20120114560 Abeta binding molecules
05/10/2012US20120114558 Aptamer-mediated drug release
05/10/2012US20120114556 Immunotherapy of autoimmune disorders using antibodies which target b-cells
05/10/2012US20120114555 Method for treating immune disorders
05/10/2012CA2826234A1 Novel vaccines against the a/h1n1 pandemic flu virus
05/10/2012CA2816929A1 Synthetic lethality in cancer
05/10/2012CA2816919A1 C-met antibody combinations
05/10/2012CA2816913A1 Novel antigen of enterococcal pathogens and use thereof as vaccine component for therapy and/or prophylaxis
05/10/2012CA2816912A1 Mmp8 inactivating antigen binding proteins
05/10/2012CA2816838A1 Method for improving the production of influenza viruses and vaccine seeds
05/10/2012CA2816808A1 High-efficiency catalysts, preparation and use thereof
05/10/2012CA2816803A1 Dual variable domain immunoglobulins and uses thereof
05/10/2012CA2816796A1 Preparation of neutralizing antibody to human herpesvirus 6 glycoprotein q1 and analysis thereof
05/10/2012CA2816745A1 Anti c-met antibodies
05/10/2012CA2816551A1 Method of treating mucosal inflammation
05/10/2012CA2816520A1 Anti-her3 antibodies and compositions
05/10/2012CA2816519A1 Pan-her antibody composition
05/10/2012CA2816454A1 Enhancement of pathogen-specific memory th17 cell responses
05/10/2012CA2816021A1 Therapeutic composition for treatment of glioblastoma
05/10/2012CA2816016A1 Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
05/10/2012CA2815266A1 Stable heterodimeric antibody design with mutations in the fc domain
05/10/2012CA2813849A1 Methods of treating rheumatoid arthritis using il-17 antagonists
05/10/2012CA2812442A1 Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy
05/10/2012CA2811948A1 Methods for treatment of brain injury utilizing biologics
05/09/2012EP2450381A1 Anti-RHD monoclonal antibodies
05/09/2012EP2450380A1 Anti-CD16 Binding Molecules
05/09/2012EP2450379A1 Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
05/09/2012EP2450378A1 Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
05/09/2012EP2450377A1 Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
05/09/2012EP2450376A2 Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
05/09/2012EP2450056A1 Prevention and treatment of synucleinopathic and amyloidogenic disease
05/09/2012EP2450055A1 Method for suppressing tumor growth by blocking fibroblast growth factor receptor, and method for diagnosing malignant neoplasms
05/09/2012EP2450054A1 New virulence factors of Streptococcus pneumoniae
05/09/2012EP2450053A1 Novel antigen of enterococcal pathogens and use thereof as vaccine component for therapy and/or prophylaxis
05/09/2012EP2450052A2 Dendritic cells
05/09/2012EP2449127A2 Polypeptides and method of treatment
05/09/2012EP2449094A1 Methods of producing humanized non-human mammals
05/09/2012EP2448970A1 Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
05/09/2012EP2448967A1 Non-human mammal model of human hematopoietic cancer
05/09/2012EP2448966A1 Immuno-conjugates and methods for producing them
05/09/2012EP2448965A1 Multimeric peptide conjugates and uses thereof
05/09/2012EP2448961A2 Targets for retrovirus associated diseases
05/09/2012EP2448599A1 Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
05/09/2012EP2448598A1 Swine influenza hemagglutinin variants
05/09/2012EP2448597A1 Adjuvated influenza vaccine and use thereof
05/09/2012EP2448596A2 Compositions and methods for diagnosing and/or treating influenza infection
05/09/2012EP2448595A1 Exosome based treatment of cancer
05/09/2012EP2448593A2 Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
05/09/2012EP2448592A1 Vaccines and compositions against streptococcus pneumoniae
05/09/2012EP2193802B1 Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
05/09/2012EP1733041B1 Anti-myostatin antibodies
05/09/2012EP1499191B1 Regulated attenuation of live vaccines to enhance cross protective immunogenicity
05/09/2012EP1441589B1 Stable liquid pharmaceutical formulation of igg antibodies
05/09/2012EP1409506B1 Methods and compositions for rnai mediated inhibition of gene expression in mammals
05/09/2012EP1399181B1 Peptide vaccines against group a streptococci
05/09/2012EP1200121B2 Fish vaccine
05/09/2012CN1826356B Binding molecules against sars-coronavirus and uses thereof
05/09/2012CN1735629B Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
05/09/2012CN1721445B Degraded TPO agonist antibody
05/09/2012CN1688339B Formulation of human antibodies for treating TNF-alpha associated disorders
05/09/2012CN1367833B Streptococcus pneumoniae proteins and nucleic acid molecules
05/09/2012CN102448991A Preparation of isolated agonist anti-edar monoclonal antibodies
05/09/2012CN102448990A Adenylyl cyclase-associated protein (CAP1) and uses thereof as a target for immuno-modulation
05/09/2012CN102448989A Anti-cd40 antibodies and uses thereof
05/09/2012CN102448986A Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
05/09/2012CN102448985A Tri- or tetraspecific antibodies
05/09/2012CN102448984A Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
05/09/2012CN102448982A Compositions and methods for modulating the activity of complement regulatory proteins on target cells
05/09/2012CN102448980A C6orf167 peptides and vaccines containing the same
05/09/2012CN102448500A Conjugation methods
1 ... 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 ... 1823